Truist Securities has initiated coverage on IDEAYA Biosciences Inc (IDYA) with a Buy rating, marking the firm’s first assessment of the biotechnology company. Headquartered in South San Francisco, California, IDEAYA is focused on the research and development of oncology-focused precision medicine, employing 131 full-time staff. The company went public on May 23, 2019, and is engaged in developing targeted therapeutics for patient populations identified through molecular diagnostics.
IDEAYA's lead product candidates include several small-molecule inhibitors aimed at treating various cancers. These include darovasertib (PKC), IDE397 (MAT2A), and IDE849 (DLL3), among others. As of November 20, 2025, the company boasts a market capitalization of $2.9 billion, with a trailing twelve-month EPS of -1.85.
Upcoming earnings reports are anticipated on May 4, 2026, and August 3, 2026, with estimated EPS of -0.97 and -0.99, respectively. The company recently reported a surprise EPS of $1.33 for Q3 2025, significantly exceeding expectations of -0.56.
The move underscores the growing interest in IDEAYA, as analyst ratings and price targets reflect professional assessments based on extensive research. While these ratings can provide valuable insights, they are based on assumptions that may not fully materialize. Investors should consider a range of factors, including company fundamentals and industry trends, when evaluating their investment choices.
Analyst consensus as of November 1, 2025, indicates a Buy rating, with 9 Strong Buy, 13 Buy, and 3 Hold ratings among a total of 25 analysts. Recent actions include Mizuho maintaining an Outperform rating and JP Morgan sustaining an Overweight position, indicating a generally favorable outlook for IDEAYA in the market.